Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
Cancer Research and Treatment. 2016;48(2):483-490 
Low Risk of Locoregional Recurrence in the Absence of Regional Radiation Therapy in Node-Positive Breast Cancer Patients Treated With Chemotherapy, Breast Conserving Surgery, and Adjuvant Breast Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics. 2013;87(2):S243
Improvement in Disease-Free Survival with Doxorubicin/Docetaxel/Cyclophosphamide (TAC) Versus 5-Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) as Adjuvant Therapy for Node-Positive Breast Cancer
Clinical Breast Cancer. 2002;3(2):103-105
Rationale and Design of a Phase III Trial of Adjuvant Sequential Epirubicin/Cyclophosphamide and Taxane Versus Concurrent Epirubicin/Taxane in Operable Node-Positive Breast Cancer
Clinical Breast Cancer. 2000;1:S52-S56
Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early-Stage Breast Cancer Patients Treated with Breast Conserving Surgery
Brachytherapy. 2017;16(3):S44
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Breast Diseases: A Year Book Quarterly. 2013;24(3):269-270
A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery
Cancer. 1998;82(11):2204-2211
Family History and Prognosis of Patients with Node-Positive Breast Cancer Treated with Adjuvant Therapy
Hereditary Cancer and Preventive Surgery. ;105-114
Randomised trial of long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone in patients with early-stage breast cancer treated with breast-conserving surgery
European Journal of Cancer. 1998;34:S40
Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
Breast Cancer Research and Treatment. 2008;114(3):589-595